Trinité-Sur-Mer Celebrates the Launch of the Class40 IBSA
A real celebration was held on September 9 in the port of La Trinité-Sur-Mer, in Brittany, for the launch of the Class40 IBSA , the brand new boat with which Alberto Bona will participate in the Route du Rhum . The transatlantic regatta is indeed the first project of the three-year program Sailing into the Future. Together that the ocean sailor started with IBSA at the beginning of 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908006032/en/
Class40 IBSA: official launch. From left to right: Sidney Gavignet, Alberto Bona, Arturo Licenziati, Giorgio Pisani, Fabrice Jover (Photo: © IBSA | Beppe Raso)
Great enthusiasm and emotion characterised the event, that took place in the small but famous Breton port, along whose mooring quays are berthed some of the most prestigious trimarans that have gone around the world and have made the history of ocean sailing. And right here, Arturo Licenziati – President and CEO of the IBSA Group – Alberto Bona and his entire team celebrated the launch of an innovative and revolutionary hull, as well as the visionary project that supports it.
“Sailing into the Future. Together is the three-year international project that we strongly pursued, because it combines several elements that for us are extremely important and distinctive: innovation, technology, commitment to sport and to the community, environmental and social responsibility”, commented Arturo Licenziati. “The whole project and this first great sporting challenge that we are preparing to face give us the opportunity to introduce to the world our vision, values and Pillars (Person, Innovation, Quality and Responsibility), the same ones that we share with sport, and with sailing in particular.”
To break the bottle on the hull – in one of the most traditional rites of the nautical world, which officially baptises the boat – will be the godmother Francesca Licenziati, niece of IBSA’s President. The launch celebration is a moment of great pride and joy, shared by the whole team, who for months worked hard on the new boat and collaborated on several fronts, concretely showing how Sailing into the Future. Together is an international project, which involves Switzerland, France and Italy in particular, and is based on strong values of inclusiveness, sustainability and teamwork.
After the technical launch on August 3, the hull designed by Sam Manuard – built by the shipyard JPS Production and hoisting the burgee of the Bellano Yacht Club – has been subject to a series of tests at sea, which allowed Alberto Bona to qualify for the Route du Rhum by sailing, between August 30 and September 5, the first 1,200 miles alone. The navigation took place in the Bay of Biscay, between Brittany and Spain, and highlighted the qualities of the hull and an excellent state of preparation in even complex weather conditions, with the winds and waves typical of the Atlantic Ocean.
“After the technical launch”, said Alberto Bona, “we had very good feedback from every perspective, from the construction of the hull to the sails, from the design to the preparation of the team. We worked to prepare the Class40 IBSA as best, and by the end of August we were ready for the qualification: on this front, we accelerated as much as possible, because after a very hot and dry summer, we had signs that the weather conditions in the Northeast Atlantic were rapidly changing.”
The Class40 IBSA thus already arrived at its launch with over 1,200 miles at sea and the first, exciting occasion of solitary navigation by Alberto Bona.
“These have been even more beautiful days than I could have imagined: on the one hand the satisfaction of now being in perfect timing for the Route du Rhum, considering that we only started the project last February; on the other the certainty of having a reliable and fast boat, the two characteristics that navigators always look for when they have to leave for a challenge like the one that awaits us from November 6, as well as all those to follow.”
“We are very satisfied with the results we have achieved so far. After many months of commitment and hard work, we have finally put into the water a boat that has all the credentials to ensure a very high performance and to be highly competitive”, commented Giorgio Pisani, Vice President Southern Europe IBSA and Project Leader. “The Class40 IBSA is the result of an approach that represents our way of being: it brings together innovation, attention to detail, continuous improvement and determination, with a vision that for IBSA always goes beyond the pharmaceutical field and beyond care.”
With this launch, the countdown to the start of the Route du Rhum has officially begun: in the coming days Alberto Bona and the team will continue working on the boat and will begin a series of targeted training sessions, in some cases working together with other teams registered in the regatta, in a series of joint tests. In mid-September, Bona will participate in the Malouine Lamotte regatta and then, on September 22, he will attend the opening day of the Genoa Boat Show, with the aim of promoting the project Sailing into the Future. Together in all its aspects, in particular that related to social inclusion.
Indeed, in its sailing programme IBSA is also committed in the field of inclusive sailing, with the involvement of prestigious yacht clubs: the Associazione Velabili, based at the Circolo Velico Lago di Lugano (Switzerland); the Société des Régates d’Antibes (France); and the Yacht Club Punta Ala (Italy). The project – which aims to support inclusive sailing, by promoting initiatives that engage people with disabilities in experiences in contact with the sea and the world of sailing – consists in supporting a team of disabled sailors in participating in the Special Olympics World Games of 2023 and in the purchase of Hansa 303 boats for the Clubs of Punta Ala and Antibes.
IBSA
IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908006032/en/
Contact information
FOR INFORMATION TO THE PRESS
IBSA Press Office – Italy
Martina Baldazzi –
martina.baldazzi@noesis.net – mob: +39 339 222 9911
Valeria Riccobono – valeria.riccobono@noesis.net – mob: +39 392 9625892
Ornella Reccia – ornella.reccia@noesis.net – mob: +39 329 393 1922
IBSA Press Office – Switzerland
Francesca Rossini – notizie@laboratoriodelleparole.net – mob: +41 77 417 93 72
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
